(1994). [URE3] as an altered Ure2 protein: evidence for a prion analog in Saccharomyces cerevisiae.
(2005). A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes.
(2006). A systematic review of prion therapeutics in experimental models.
(2006). A yeast-based assay to isolate drugs active against mammalian prions.
(2003). Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene.
(2001). Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
(2008). Cell models of prion infection.
(2007). Centrally acting antihypertensive agents: an update.
(1982). Clonidine hydrochloride.
(2004). Cultured peripheral neuroglial cells are highly permissive to sheep prion infection.
(2003). Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.
(1984). Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen.
(1997). Effectiveness of anthracycline against experimental prion disease in Syrian hamsters.
(1999). Elimination of prions by branched polyamines and implications for therapeutics.
(2003). Evaluation of quinacrine treatment for prion diseases.
(2001). Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein.
(1983). Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.
(2003). Humanized knock-in mice expressing chimeric prion protein showed varied susceptibility to different human prions.
(1988). Immunoaffinity purification and neutralization of scrapie prion infectivity.
(2003). Isolation of drugs active against mammalian prions using a yeast-based screening assay.
(2000). Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation.
(2001). Markedly increased susceptibility to natural sheep scrapie of transgenic mice expressing ovine prp.
(2004). Modulation of prion protein oligomerization, aggregation, and beta-sheet conversion by 4,49-dianilino-1,19-binaphthyl-5,59-sulfonate (bis-ANS).
(2007). Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity.
(2000). Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent.
(2007). Peptide aptamers expressed in the secretory pathway interfere with cellular PrPSc formation.
(1995). Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein.
(2006). Prion proteins as genetic material in fungi.
(2007). Prion strain- and species-dependent effects of antiprion molecules in primary neuronal cultures.
(2002). Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model.
(2000). Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides.
(2005). Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells.
(1999). Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the proteaseresistant state.
(2005). Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.
(1989). Tacrine in Alzheimer’s disease.
(2007). Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice.
(2002). Tetracyclines affect prion infectivity.
(1994). Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein.
(2006). Using budding yeast to screen for anti-prion drugs.
(1995). Why imidazoline receptor modulator in the treatment of hypertension?